AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03168295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet then Dapagliflozin 10mg
Description: Placebo then SGLT2 inhibitor - Dapagliflozin
Study NCT03168295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet then Dapagliflozin 10mg
Description: Placebo then SGLT2 inhibitor - Dapagliflozin
Study NCT03704155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
Study NCT03704155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion.
Study NCT03704155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion.
Study NCT03850652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic (Synergy-1) + Iron supplement
Description: In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
Study NCT03850652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Maltodextrin) + Iron Supplement
Description: participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
Study NCT00121654 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal cord stimulation
Description: Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
Study NCT03069079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene advice, non surgical periodontal treatment
Description: For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
Study NCT01873859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
Study NCT04082962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Description: Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
Study NCT03043079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity
Description: Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
Study NCT03043079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity
Description: Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
Study NCT00491504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
Study NCT00491504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 sprays in each nostril
Study NCT04820608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linking
Description: Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.
Study NCT04971057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimedia information program of renal biopsy
Description: Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
Study NCT01518491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDOX Hydrogel
Description: NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
Study NCT01518491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAC Alone
Description: Patients will receive VAC therapy three time weekly for eight weeks
Study NCT01214083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine + high-dose naltrexone (150 mg)
Description: All subjects will be evaluated weekly for 12 weeks.
Study NCT01214083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose naltrexone (150 mg) alone
Description: All subjects will be evaluated weekly for 12 weeks.
Study NCT01214083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose naltrexone (50 mg) alone
Description: All subjects will be evaluated weekly for 12 weeks.
Study NCT02942602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study NCT02942602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 g
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study NCT02942602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 2g
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study NCT04043013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Taurus® (Rocky Mountain©) Brackets
Study NCT04043013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Clip® SL3 High Torque (3M Unitek©)
Study NCT04043013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tip-Edge Plus® (TP Orthodontics©)
Study NCT04043013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Victory® (3M Unitek©)
Study NCT01811277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX sequential S-1
Description: 4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
Study NCT03416595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N1115 Probiotic Supplement
Description: Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
Study NCT03416595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
Study NCT03845946 — intervention group
Intervention type: BEHAVIORAL
Intervention: angioedema
Description: electronic tracking book
Study NCT03109366 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online patient-provider communication service
Study NCT01938950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Study NCT02375308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HDT
Description: 20 sessions, individual psychotherapy
Study NCT02375308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACDT
Description: 20 sessions, individual psychotherapy
Study NCT02888912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQUIA
Description: Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
Study NCT02888912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradia Direct Posterior
Description: The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
Study NCT01938950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Study NCT01938950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and Resistance Exercise
Study NCT04299061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire
Description: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. Walking = 3.3 METs Moderate Intensity = 4.0 METs Vigorous Intensity = 8.0 METs Total MET-minutes/week = Walk (METs\*min\*days) + Mod (METs\*min\*days) + Vig (METs\*min\*days)~1. Low: • No activity is reported OR • Some activity is reported but not enough to meet Categories 2 or 3. 2. Moderate: • 3 or more days of vigorous activity of at least 20 minutes per day OR • 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-minutes/week. 3. High: • Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week
Study NCT04299061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Description: The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month.The client self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of 5or greater indicates a poor sleeper.
Study NCT04299061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Awareness Questionnaire - prepared by the researchers
Description: It consists of 13 questions to assess the physical activity level awareness of students. The questionnaire was prepared by the researchers therefore it does not have a validation.
Study NCT04299061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perceived Stress Scale
Description: The Perceived Stress Scale (PSS) is a classic stress assessment instrument that helps understand how different situations affect feelings and perceived stress. The questions in this scale ask about feelings and thoughts during the last month. It consists of 14 questions.
Study NCT02942602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study NCT02942602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Study NCT02408575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Notched filtering (verum)
Description: Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
Study NCT02408575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No filtering (placebo)
Description: Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering
Study NCT02643901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: single SC injection
Study NCT00251095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxol
Study NCT00251095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOCOSOL Paclitaxel
Description: 100 mg/m2/week
Study NCT03048344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORH-2014
Description: ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
Study NCT03048344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORH-2014
Description: ORH-2014 capsule at recommended dose orally.
Study NCT01385410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer mother support for continued exclusive breastfeeding
Description: Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
Study NCT00331630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00331630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: 30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT03801629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Morphine Dose
Description: Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
Study NCT03801629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Morphine Dose
Description: Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
Study NCT04539821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VCPM
Description: VCPM is a multi-component intervention consisting of already-established care processes and materials.
Study NCT00320775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap.
Study NCT00320775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEGF Trap
Description: Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap.
Study NCT01828580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active laparoscope positioner (AutoLap)
Study NCT03859414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Dose 1
Description: CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
Study NCT01452529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate q24h film-coated tablets
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
Study NCT01452529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match hydrocodone bitartrate q24h tablets
Description: Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
Study NCT00004843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parathyroidectomy
Description: Standard parathyroidectomy with a bilateral approach
Study NCT00004843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Usual care
Study NCT01375933 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NicVAX Vaccine
Description: NicVAX Vaccine given 6 times over 6 months
Study NCT03859414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Dose 2
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
Study NCT03859414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supra-therapeutic Dose
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
Study NCT03859414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CHF 5993 placebo pMDI
Study NCT02691182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.